AzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial

AzurRX BioPharma (NASDAQ:AZRX) has announced it has reached its enrollment target of 30 to 35 patients for its ongoing Phase...

AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency

AzurRx BioPharma (NASDAQ:AZRX) a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced, in partnership with Mayoly...